Equities

Linical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2183:TYO

Linical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)317.00
  • Today's Change3.00 / 0.96%
  • Shares traded18.30k
  • 1 Year change-8.91%
  • Beta0.5749
Data delayed at least 15 minutes, as of Feb 06 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

  • Revenue in JPY (TTM)9.87bn
  • Net income in JPY-1.19bn
  • Incorporated2005
  • Employees598.00
  • Location
    Linical Co Ltd10F, Shin-Osaka Brick Bldg1-6-1, MiyaharaYodogawa-kuOSAKA-SHI 532-0003JapanJPN
  • Phone+81 661502478
  • Fax+81 661502675
  • Websitehttps://www.linical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ribomic Inc0.00-1.05bn4.51bn25.00--1.32-----23.81-23.810.0063.040.00----0.00-31.15-29.95-32.30-31.15-------2,725.9525.20--0.00-----55.550.5173---6.86--
Modalis Therapeutics Corp0.00-2.06bn5.16bn14.00--1.75-----27.71-27.710.0033.640.00----0.00-66.07-35.65-74.94-36.83-------1,981.18----0.0888------44.90---67.80--
D.Western Therapeutics Institute Inc419.76m-1.06bn5.43bn21.00--3.63--12.92-24.98-24.989.4827.560.19210.41942.7119,988,760.00-48.31-24.39-52.24-26.5889.7593.00-251.53-142.258.69-274.870.2606--10.09-4.07-58.82------
Carna Biosciences, Inc.544.45m-2.19bn5.97bn63.00--6.91--10.97-114.83-114.8328.5445.150.24131.127.388,642,000.00-97.06-27.56-106.60-31.6268.3987.57-402.24-93.048.23--0.3498---60.87-27.64-88.97---20.85--
Cyfuse Biomedical KK-100.00bn-100.00bn6.53bn21.00--2.20----------298.18------------------------5.80--0.3038---10.91---48.03------
Noile-Immune Biotech Inc7.14m-782.47m6.58bn25.00--1.60--921.44-18.07-18.070.16595.160.00160.000.0668285,720.00-17.08---17.32--30.00---10,954.38--60.62--0.00---97.61--14.65------
TMS Co Ltd0.00-670.20m6.60bn18.00--2.20-----15.72-15.720.0065.780.00----0.00-21.59---22.41----------23.99--0.00------31.20------
PRISM BioLab Co Ltd677.33m-833.70m7.09bn35.00--2.61--10.47-22.84-22.8418.5473.590.1779--12.5819,352,290.00-21.90---26.79--39.83---123.09------0.00--121.62--20.56------
OncoTherapy Science, Inc.956.86m-824.72m7.53bn47.00--4.11--7.87-2.90-2.903.384.860.54946.2421.5020,358,640.00-47.35-63.66-58.01-77.438.44-0.3852-86.19-184.758.21-567.860.0139--22.9318.8636.71---70.80--
Linical Co Ltd9.87bn-1.19bn7.77bn598.00--1.17--0.787-52.52-52.52437.00267.760.6226--3.6916,505,640.00-7.482.59-13.504.1921.6129.24-12.023.74----0.258477.26-15.20-0.9283-259.37---42.014.24
Medinet Co Ltd810.29m-1.36bn7.97bn107.00--2.10--9.84-5.15-5.153.0614.270.162814.023.357,572,813.00-27.37-22.42-28.82-23.6413.5417.68-168.10-173.5915.28--0.00--5.440.6867-6.67--10.06--
Chiome Bioscience Inc727.99m-905.53m8.06bn47.00--6.31--11.07-13.44-13.4410.8918.370.44896.2313.4515,489,230.00-55.84-50.30-70.30-59.7357.3356.21-124.39-190.325.37-728.130.0597--14.4111.7716.33------
Tsubota Laboratory Inc973.21m-172.89m8.28bn17.00--6.41--8.51-6.79-6.7937.6150.080.47330.67264.0057,247,590.00-8.410.1041-12.170.151780.2771.43-17.760.22162.89--0.05860.00101.4925.17132.08132.7026.42--
Chordia Therapeutics Inc0.00-1.46bn8.82bn20.00--3.70-----21.23-21.230.0032.670.00----0.00-46.77---49.97-------------222.950.00------2.26------
BrightPath Biotherapeutics Co Ltd1.11m-1.08bn8.96bn24.00--4.96--8,072.24-11.59-11.590.011713.700.0007----46,250.00-63.35-59.65-74.36-63.7897.6673.74-96,860.36-28,727.67---1,103.910.00--1,473.61-36.871.45---58.41--
Nano Holdings Inc141.92m-757.17m10.61bn20.00--3.80--74.75-10.69-10.692.0136.620.03598.1716.767,095,800.00-18.65-23.68-21.92-25.3772.6482.69-533.54-746.834.10--0.00---19.92-27.80-7.10------
Data as of Feb 06 2026. Currency figures normalised to Linical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

1.45%Per cent of shares held by top holders
HolderShares% Held
Sawakami Asset Management, Inc.as of 31 Oct 2025348.70k1.41%
Amova Asset Management Co., Ltd.as of 07 Nov 20246.20k0.03%
Dimensional Fund Advisors LPas of 31 Oct 20252.60k0.01%
State Street Global Advisors (Japan) Co. Ltd.as of 05 Mar 2024600.000.00%
Nomura Asset Management Co., Ltd.as of 29 Sep 2025400.000.00%
Resona Asset Management Co., Ltd.as of 10 Dec 2024300.000.00%
Mitsubishi UFJ Asset Management Co., Ltd.as of 14 Mar 2024100.000.00%
Norinchukin Zenkyoren Asset Management Co., Ltd.as of 27 May 2024100.000.00%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 10 Sep 20250.000.00%
Shinkin Asset Management Co., Ltd.as of 18 Jul 20250.000.00%
More ▼
Data from 22 Sep 2025 - 23 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.